-
US Stock Futures Tumble Ahead Of Durable-Goods Orders, Jobless Claims Data
Thursday, February 27, 2014 - 8:18am | 443Pre-open movers US stock futures fell in early pre-market trading, ahead of economic data. Data on durable goods orders for January and weekly jobless claims will be released at 8:30 a.m. ET. The Kansas City Fed manufacturing index for February will be released at 11:00 a.m. ET. Futures for the...
-
Roth Says Use of New Promacta May Provide 'Meaningful' Royalties, EPS Growth to Ligand
Monday, February 3, 2014 - 1:41pm | 73An analyst at Roth Capital, Joseph Pantginis, earlier noted Ligand (NASDAQ: LGND) may see EPS growth of up to $0.35 over the next few years, as a result of “meaningful” royalty income from Promacta(R). The product is used to treat persons with severe aplastic anemia (SAA). Pantginis maintains a...
-
Morning Market Movers
Wednesday, January 22, 2014 - 11:22am | 115Luna Innovations (NASDAQ: LUNA) jumped 95.45% to $2.58 as the company announced its plans to sell its shape-sensing technology to Intuitive Surgical (NASDAQ: ISRG). VisionChina Media (NASDAQ: VISN) rose 33.40% to $32.27 after the company announced an exclusive strategic cooperation with Baidu...
-
UPDATE: Luna Announces Sale of Shape-Sensing Technology for Medical Applications
Wednesday, January 22, 2014 - 10:05am | 958Luna Innovations Incorporated (NASDAQ: LUNA), which develops and manufactures new-generation products for the telecommunications, aerospace, automotive, energy and defense markets, today announced the sale of its shape-sensing technology for medical applications to Intuitive Surgical, Inc. (NASDAQ...
-
Benzinga's Top #PreMarket Losers
Wednesday, January 8, 2014 - 9:20am | 114Origin Agritech (NASDAQ: SEED) shares fell 17.70% to $2.00 in the pre-market trading after the company reported unaudited financial results for the year ended September 30, 2013. Ballard Power Systems (NASDAQ: BLDP) dipped 5.26% to $2.34 in the pre-market session after rising 33.51% on Tuesday....
-
Benzinga's Volume Movers
Tuesday, January 7, 2014 - 12:03pm | 163Neurocrine Biosciences (NASDAQ: NBIX) shares moved up 76.95% to $17.27. The volume of Neurocrine Biosciences shares traded was 4406% higher than normal. Neurocrine Biosciences reported positive results of VMAT2 inhibitor NBI-98854 in Kinect 2 study. Epizyme (NASDAQ: EPZM) shares rose 66.84% to $34...
-
Morning Market Movers
Tuesday, January 7, 2014 - 11:07am | 118Neurocrine Biosciences (NASDAQ: NBIX) jumped 60.40% to $15.66 after the company reported positive results of VMAT2 inhibitor NBI-98854 in Kinect 2 study. Epizyme (NASDAQ: EPZM) moved up 55.32% to $31.84 after the company reported two major milestone achievements. It announced the achievement of a...
-
Benzinga's Top #PreMarket Gainers
Tuesday, January 7, 2014 - 9:07am | 117Neurocrine Biosciences (NASDAQ: NBIX) shares jumped 60.35% to $15.65 in pre-market trading after the company reported positive results of VMAT2 inhibitor NBI-98854 in Kinect 2 study. Origin Agritech (NASDAQ: SEED) shares gained 8.59% to $2.78 in the pre-market. Origin Agritech is estimated to...
-
Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study
Monday, January 6, 2014 - 5:02pm | 1939Neurocrine Biosciences (NASDAQ: NBIX) announced today that NBI-98854, a small molecule VMAT2 inhibitor, showed a statistically significant and clinically meaningful reduction in tardive dyskinesia symptoms in the Phase IIb Kinect 2 study. The pre-specified primary endpoint was the change-from-...
-
Ligand Announces Positive Preclinical Data on Small-Molecule G-CSF Receptor Agonist at ASH
Monday, December 9, 2013 - 6:57am | 118Ligand Pharmaceuticals (NASDAQ: LGND) announced that data from preclinical studies on its granulocyte colony stimulating factor (G-CSF) receptor agonist program were featured in a poster presentation today at the 55th Annual Meeting of the American Society of...
-
Benzinga's Top Initiations
Friday, December 6, 2013 - 9:14am | 152Analysts at Pivotal Research initiated coverage on shares of Salesforce.com (NYSE: CRM) with a “buy” rating. The target price for Salesforce.com is set to $66. Salesforce.com's shares closed at $53.05 yesterday. Bank of America initiated coverage on shares of Lexicon Pharmaceuticals (NASDAQ: LXRX...
-
Benzinga's Top #PreMarket Losers
Tuesday, December 3, 2013 - 9:43am | 120Krispy Kreme Doughnuts (NYSE: KKD) dipped 14.05% to $21.10 after the company issued downbeat forecast for fiscal 2015. Lexicon Pharmaceuticals (NASDAQ: LXRX) dipped 11.64% to $2.05 in the pre-market session after the company completed Phase 2 study Of LX1033 In IBS-d. Medallion Financial (NASDAQ...
-
US Stock Futures Signal Lower Start On Wall Street
Tuesday, December 3, 2013 - 8:03am | 499Pre-open movers US stock futures dropped in early pre-market trade. Data on motor vehicle sales will be released today. Futures for the Dow Jones Industrial Average tumbled 62 points to 15,936.00, while the Standard & Poor's 500 index futures fell 5.80 points to 1,793.90. Futures for the...
-
Lexicon Phase 2 Study Of LX1033 In IBS-d Shows Differences Between Placebo and LX1033 were Not Statistically Significant
Tuesday, December 3, 2013 - 7:07am | 214Lexicon Pharmaceuticals (Nasdaq: LXRX) today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome (IBS-d). LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is...
-
Stocks Hitting 52-Week Lows
Wednesday, November 20, 2013 - 11:15am | 119Zalicus (NASDAQ: ZLCS) shares reached a new 52-week low of $1.00. Zalicus's trailing-twelve-month ROE is -137.50%. Metabolix (NASDAQ: MBLX) shares tumbled 5.75% to reach a new 52-week low of $0.82. Metabolix shares have dropped 29.84% over the past 52 weeks, while the S&P 500 index has gained...